These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 12876900)

  • 21. Therapeutic HIV vaccines show promise.
    Abbott A
    Nature; 2010 Jul; 466(7306):539. PubMed ID: 20671679
    [No Abstract]   [Full Text] [Related]  

  • 22. AIDS in the Third World: how to stop the HIV infection?
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):65-80. PubMed ID: 17550059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of incidence function in vaccine-induced backward bifurcation in some HIV models.
    Sharomi O; Podder CN; Gumel AB; Elbasha EH; Watmough J
    Math Biosci; 2007 Dec; 210(2):436-63. PubMed ID: 17707441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
    Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
    J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twenty years of HIV-1 research: what the future holds.
    Imami N; Gotch F
    Nat Immunol; 2003 Jun; 4(6):501. PubMed ID: 12774067
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines.
    Ferrantelli F; Cafaro A; Ensoli B
    Curr Opin Biotechnol; 2004 Dec; 15(6):543-56. PubMed ID: 15560981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of the transmission dynamics of the HIV/AIDS epidemic on sexual behaviour: a new hypothesis to explain recent increases in risk taking-behaviour among men who have sex with men.
    Boily MC; Godin G; Hogben M; Sherr L; Bastos FI
    Med Hypotheses; 2005; 65(2):215-26. PubMed ID: 15922091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
    Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
    J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.
    Garnett GP
    J Infect Dis; 2005 Feb; 191 Suppl 1():S97-106. PubMed ID: 15627236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model.
    Scott S; Mossong J; Moss WJ; Cutts FT; Cousens S
    Int J Epidemiol; 2008 Apr; 37(2):356-67. PubMed ID: 18234739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of therapeutic vaccines in the control of HIV-1.
    Kinloch-de Loes S
    J Antimicrob Chemother; 2004 Apr; 53(4):562-6. PubMed ID: 14985273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.
    Dowdy DW; Chaisson RE; Moulton LH; Dorman SE
    AIDS; 2006 Mar; 20(5):751-62. PubMed ID: 16514306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [HIV genetic diversity and its consequences].
    Roquebert B; Damond F; Brun-Vézinet F; Descamps D
    Pathol Biol (Paris); 2009 Mar; 57(2):142-8. PubMed ID: 18511216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies toward restoration of immunity to HIV.
    Autran B
    AIDS; 2002 Jul; 16(10):4-6. PubMed ID: 12146461
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic vaccines against HIV need international partnerships.
    Autran B; Debré P; Walker B; Katlama C
    Nat Rev Immunol; 2003 Jun; 3(6):503-8. PubMed ID: 12776210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda.
    Gray RH; Li X; Wawer MJ; Gange SJ; Serwadda D; Sewankambo NK; Moore R; Wabwire-Mangen F; Lutalo T; Quinn TC;
    AIDS; 2003 Sep; 17(13):1941-51. PubMed ID: 12960827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.